Function and Targeting of CCR6/CCL20 in Autoimmune Psoriasiform Skin Disease

CCR6/CCL20 在自身免疫性银屑病皮肤病中的功能和靶向

基本信息

  • 批准号:
    8502109
  • 负责人:
  • 金额:
    $ 31.43万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2013
  • 资助国家:
    美国
  • 起止时间:
    2013-09-01 至 2018-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Th17-associated cells and signaling pathways are clearly important in the development of multiple autoimmune processes, including rheumatoid arthritis, multiple sclerosis, and psoriasis. IL23 is a prototypical driver of Th17-mediated inflammation, and we and others have shown that repeated injections of recombinant IL23 in mouse skin result in a psoriasiform dermatitis that mimics many of the features of human psoriasis in as little as 5 days. Among the ~20 known chemokine receptors, CC chemokine receptor-6 (CCR6) is particularly important for Th17-directed immune activity since it is both a marker for T cells that express the Th17 phenotype and a critical participant in several mouse models of autoimmune disease, including autoimmune encephalitis, collagen-induced arthritis, and psoriasis. We have previously shown that CCR6-deficient mice fail to develop psoriasiform dermatitis in skin following IL23 injection. Current models suggest that IL23 produced by dendritic cells (DCs) act to sustain dermal CC chemokine receptor-6 (CCR6)-expressing Th17 cells which then produce IL22 as a major downstream effector that stimulates epidermal hyperplasia through STAT3- mediated mechanisms in human skin. Positive feedback is provided by epidermal and dermal production of CCL20, the CCR6 ligand, potentially recruiting more CCR6+ T cells or CCR6+ antigen-presenting cells into inflamed psoriatic skin. While data from human studies are just beginning to implicate ?¿T cells in psoriasis and other autoimmune disease, our published data demonstrate that a novel population of CCR6+, V?3- T cell receptor (TCR) ?¿ low (GDL) T cells, distinct from resident dendritic epidermal ?¿ T cells (DETC), accumulates in murine epidermis following exposure to IL23 and is a major producer of IL22 and IL17 in murine epidermis. We hypothesize that 1) CCR6+ GDL T cells in skin may be critical innate immune cells for the delivery of IL22 and other cytokines that regulate epidermal hyperplasia and inflammation in skin in conditions such as psoriasis and 2) that antagonists of CCR6 or CCL20 would be effective therapeutic agents in several Th17- mediated autoimmune processes, including psoriasis, because of their effects on the trafficking and/or function of CCR6-expressing cells. Based on this hypothesis, we seek to better define the roles of CCR6 and ?¿ T cells in an IL23- and imiquimod-induced models of psoriasisform dermatitis in mice and to use novel computational methods to identify small molecule lead compounds that antagonize the function of either CCR6 or its ligand, CCL20. Our results will be validated with a SCID-hu psoriasis skin xenotransplant model.
描述(由申请人提供):Th 17相关细胞和信号通路在多种自身免疫过程(包括类风湿性关节炎、多发性硬化症和银屑病)的发展中显然很重要。IL 23是Th 17介导的炎症的原型驱动因子,我们和其他人已经表明,在小鼠皮肤中重复注射重组IL 23导致银屑病样皮炎,其在短短5天内模仿了人类银屑病的许多特征。在约20种已知的趋化因子受体中,CC趋化因子受体-6(CCR 6)对于Th 17导向的免疫活性特别重要,因为它既是表达Th 17表型的T细胞的标志物,也是几种自身免疫性疾病小鼠模型(包括自身免疫性脑炎、胶原诱导的关节炎和银屑病)的关键参与者。我们先前已经表明,CCR 6缺陷小鼠在IL 23注射后不能在皮肤中发展银屑病样皮炎。目前的模型表明,由树突状细胞(DC)产生的IL 23的作用,以维持皮肤CC趋化因子受体-6(CCR 6)表达的Th 17细胞,然后产生IL 22作为一个主要的下游效应,刺激表皮增生,通过STAT 3介导的机制在人类皮肤。正反馈由CCL 20(CCR 6配体)的表皮和真皮产生提供,潜在地将更多的CCR 6 + T细胞或CCR 6+抗原呈递细胞募集到发炎的银屑病皮肤中。而人类研究的数据才刚刚开始暗示?T细胞在银屑病和其他自身免疫性疾病,我们发表的数据表明,一个新的群体CCR 6+,V?3-T细胞受体(TCR)?低(GDL)T细胞,不同于居民树突状表皮?T细胞(DETC)在暴露于IL 23后在鼠表皮中积累,并且是鼠表皮中IL 22和IL 17的主要产生者。我们假设:1)皮肤中的CCR 6 + GDL T细胞可能是递送IL 22和其他细胞因子的关键先天免疫细胞,所述细胞因子在诸如银屑病的病症中调节皮肤中的表皮增生和炎症,和2)CCR 6或CCL 20的拮抗剂将是几种Th 17介导的自身免疫过程(包括银屑病)中的有效治疗剂,因为它们对表达CCR 6的细胞的运输和/或功能有影响。基于这一假设,我们试图更好地定义CCR 6和?IL 23和咪喹莫特诱导的小鼠银屑病样皮炎模型中的T细胞,并使用新的计算方法来鉴定拮抗CCR 6或其配体CCL 20功能的小分子先导化合物。我们的研究结果将与SCID-hu银屑病皮肤异种移植模型进行验证。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Sam T Hwang其他文献

Sam T Hwang的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Sam T Hwang', 18)}}的其他基金

Function and Targeting of CCR6/CCL20 in Autoimmune Psoriasiform Skin Disease
CCR6/CCL20 在自身免疫性银屑病皮肤病中的功能和靶向
  • 批准号:
    8906749
  • 财政年份:
    2013
  • 资助金额:
    $ 31.43万
  • 项目类别:
Function and Targeting of CCR6/CCL20 in Autoimmune Psoriasiform Skin Disease
CCR6/CCL20 在自身免疫性银屑病皮肤病中的功能和靶向
  • 批准号:
    9125724
  • 财政年份:
    2013
  • 资助金额:
    $ 31.43万
  • 项目类别:

相似海外基金

Tri-Signal Artificial Antigen Presenting Cells for Cancer Immunotherapy
用于癌症免疫治疗的三信号人工抗原呈递细胞
  • 批准号:
    10751133
  • 财政年份:
    2023
  • 资助金额:
    $ 31.43万
  • 项目类别:
Microfluidic Precision Engineered Artificial Antigen Presenting Cells for Cancer Immunotherapy
用于癌症免疫治疗的微流控精密工程人工抗原呈递细胞
  • 批准号:
    10696138
  • 财政年份:
    2022
  • 资助金额:
    $ 31.43万
  • 项目类别:
The role of microglia as antigen presenting cells in Globoid Cell Leukodystrophy
小胶质细胞作为抗原呈递细胞在球状细胞脑白质营养不良中的作用
  • 批准号:
    10663066
  • 财政年份:
    2022
  • 资助金额:
    $ 31.43万
  • 项目类别:
The role of microglia as antigen presenting cells in Globoid Cell Leukodystrophy
小胶质细胞作为抗原呈递细胞在球状细胞脑白质营养不良中的作用
  • 批准号:
    10537159
  • 财政年份:
    2022
  • 资助金额:
    $ 31.43万
  • 项目类别:
Analysis of the function of antigen-presenting cells present in the stroma of colorectal cancer and the intracellular microbiome
结直肠癌基质中抗原呈递细胞和细胞内微生物组的功能分析
  • 批准号:
    21K08723
  • 财政年份:
    2021
  • 资助金额:
    $ 31.43万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Class II artificial antigen presenting cells for cancer immunotherapy
用于癌症免疫治疗的 II 类人工抗原呈递细胞
  • 批准号:
    10156950
  • 财政年份:
    2021
  • 资助金额:
    $ 31.43万
  • 项目类别:
The role of CX3CR1+ antigen presenting cells in T cell selection and central tolerance"
CX3CR1抗原呈递细胞在T细胞选择和中枢耐受中的作用"
  • 批准号:
    10631854
  • 财政年份:
    2021
  • 资助金额:
    $ 31.43万
  • 项目类别:
Reprogramming Cancer Cells into Antigen Presenting Cells: Cancer Vaccination with mRNA Enabled by Charge-Altering Releasable Transporters
将癌细胞重编程为抗原呈递细胞:通过改变电荷的可释放转运蛋白实现 mRNA 的癌症疫苗接种
  • 批准号:
    10153927
  • 财政年份:
    2021
  • 资助金额:
    $ 31.43万
  • 项目类别:
Class II artificial antigen presenting cells for cancer immunotherapy
用于癌症免疫治疗的 II 类人工抗原呈递细胞
  • 批准号:
    10331830
  • 财政年份:
    2021
  • 资助金额:
    $ 31.43万
  • 项目类别:
Analysis on detrimental interplay between pathogenic helper T cells, inflammatory antigen-presenting cells and disease-associated microglia in chronic pathogenesis of multiple sclerosis
多发性硬化症慢性发病机制中致病性辅助 T 细胞、炎症抗原呈递细胞和疾病相关小胶质细胞之间的有害相互作用分析
  • 批准号:
    20K16294
  • 财政年份:
    2020
  • 资助金额:
    $ 31.43万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了